Haigh Adrian 4
4 · FENNEC PHARMACEUTICALS INC. · Filed Apr 22, 2024
Insider Transaction Report
Form 4
Haigh Adrian
Director
Transactions
- Sale
Common Shares
2024-04-22$9.32/sh−22,223$207,029→ 0 total - Exercise/Conversion
Common Shares
2024-04-19$2.31/sh+22,222$51,333→ 22,222 total - Exercise/Conversion
Option
2024-04-22$2.31/sh−22,223$51,335→ 360,246 totalExercise: $2.31From: 2014-04-25Exp: 2024-04-25→ Common Shares (22,223 underlying) - Exercise/Conversion
Common Shares
2024-04-22$2.31/sh+22,223$51,335→ 22,223 total - Sale
Common Shares
2024-04-19$9.34/sh−22,222$207,442→ 0 total - Exercise/Conversion
Option
2024-04-19$2.31/sh−22,222$51,333→ 382,469 totalExercise: $2.31From: 2014-04-25Exp: 2024-04-25→ Common Shares (22,222 underlying)
Footnotes (6)
- [F1]Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023.
- [F2]Shares disposed pursuant to a 10b5-1 plan dated August 17, 2023.
- [F3]Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023.
- [F4]Shares disposed pursuant to a 10b5-1 plan dated August 17, 2023.
- [F5]Represents option exercise pursuant to a 10b5-1 plan dated August 17, 2023.
- [F6]Represents option exercise pursuant to a 10b5-1 plan dated August 17, 2023.